Leucovorin

Generic Name
Leucovorin
Brand Names
EnBrace HR, EnLyte, Lederle Leucovorin
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
58-05-9
Unique Ingredient Identifier
Q573I9DVLP
Background

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions
Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
Associated Therapies
-
Clinical Trials
Related News
nature.com
·

Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in ...

Article references on cancer treatments, focusing on HER2-targeted therapies, chemotherapy combinations, and immune microenvironment impacts in gastric and gastro-oesophageal junction cancers.
onclive.com
·

Zolbetuximab Plus Chemotherapy Wins EU Approval for Advanced CLDN18.2+ Gastric/GEJ Cancer

The European Commission approved zolbetuximab (Vyloy) plus chemotherapy for HER2-negative, Claudin 18.2-positive gastric and gastroesophageal junction cancers. Zolbetuximab, targeting CLDN18.2, showed improved progression-free and overall survival in phase 3 trials SPOTLIGHT and GLOW. Common side effects included vomiting, nausea, and decreased appetite.

Related Clinical Trials:

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
medpagetoday.com
·

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

Preoperative chemoradiotherapy did not improve survival over perioperative chemotherapy alone in resectable gastric and gastroesophageal junction adenocarcinoma, according to TOPGEAR data. Median overall survival was 46.4 months vs 49.4 months, with no significant differences in progression-free survival. However, preoperative chemoradiotherapy significantly improved pathological outcomes, including complete response rates and tumor downstaging.

Related Clinical Trials:

Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
targetedonc.com
·

Safety, Activity Seen with Frontline Zanidatamab Plus Chemo ± Bevacizumab in HER2+ mCRC

Zanidatamab (ZW25) plus mFOLFOX6-2 with or without bevacizumab showed 83.3% and 100% confirmed overall response rates, respectively, in a phase 2 study for HER2-positive mCRC, with manageable safety profile and no treatment-related deaths.

Related Clinical Trials:

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
cancernetwork.com
·

Omission of 5-FU From Combo Therapy May Improve Results in Advanced GI Cancers

Omitting 5-fluorouracil (5-FU) from first-line multidrug regimens in advanced gastrointestinal cancers reduced toxicity without compromising efficacy, according to a study in the Journal of the National Comprehensive Cancer Network. No significant difference in overall survival was found when 5-FU bolus was omitted, regardless of regimen or cancer type. The study suggests that the bolus component of 5-FU may not be necessary.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy